Mitochondrial complex‐I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer’s disease

2022 ◽  
Author(s):  
Tatsuhiro Terada ◽  
Joseph Therriault ◽  
Min Su Kang ◽  
Melissa Savard ◽  
Tharick Ali Pascoal ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex

scholarly journals Modulation of Mitochondrial Complex I Activity Averts Cognitive Decline in Multiple Animal Models of Familial Alzheimer's Disease

EBioMedicine ◽  
2015 ◽  
Vol 2 (4) ◽  
pp. 294-305 ◽  
Author(s):  
Liang Zhang ◽  
Song Zhang ◽  
Izumi Maezawa ◽  
Sergey Trushin ◽  
Paras Minhas ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Animal Models ◽  
Cognitive Decline ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Familial Alzheimer’S Disease ◽  
Familial Alzheimer's Disease ◽  
Complex I Activity

scholarly journals Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Tatsuhiro Terada ◽  
Joseph Therriault ◽  
Min Su Peter Kang ◽  
Melissa Savard ◽  
Tharick Ali Pascoal ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mitochondrial Dysfunction ◽  
Complex I ◽  
Clinical Symptoms ◽  
Mitochondrial Complex I ◽  
Braak Stage ◽  
Mitochondrial Complex ◽  
Temporal Area

Abstract Background Mitochondrial electron transport chain abnormalities have been reported in postmortem pathological specimens of Alzheimer’s disease (AD). However, it remains unclear how amyloid and tau are associated with mitochondrial dysfunction in vivo. The purpose of this study is to assess the local relationships between mitochondrial dysfunction and AD pathophysiology in mild AD using the novel mitochondrial complex I PET imaging agent [18F]BCPP-EF. Methods Thirty-two amyloid and tau positive mild stage AD dementia patients (mean age ± SD: 71.1 ± 8.3 years) underwent a series of PET measurements with [18F]BCPP-EF mitochondrial function, [11C]PBB3 for tau deposition, and [11C] PiB for amyloid deposition. Age-matched normal control subjects were also recruited. Inter and intrasubject comparisons of levels of mitochondrial complex I activity, amyloid and tau deposition were performed. Results The [18F]BCPP-EF uptake was significantly lower in the medial temporal area, highlighting the importance of the mitochondrial involvement in AD pathology. [11C]PBB3 uptake was greater in the temporo-parietal regions in AD. Region of interest analysis in the Braak stage I-II region showed significant negative correlation between [18F]BCPP-EF SUVR and [11C]PBB3 BPND (R = 0.2679, p = 0.04), but not [11C] PiB SUVR. Conclusions Our results indicated that mitochondrial complex I is closely associated with tau load evaluated by [11C]PBB3, which might suffer in the presence of its off-target binding. The absence of association between mitochondrial complex I dysfunction with amyloid load suggests that mitochondrial dysfunction in the trans-entorhinal and entorhinal region is a reflection of neuronal injury occurring in the brain of mild AD.

Reduced Levels of Mitochondrial Complex I Subunit NDUFB8 and Linked Complex I + III Oxidoreductase Activity in the TgCRND8 Mouse Model of Alzheimer's Disease

2014 ◽  
Vol 39 (2) ◽  
pp. 347-355 ◽  
Author(s):  
Beverly M. Francis ◽  
Jimao Yang ◽  
Byung Jun Song ◽  
Saurabh Gupta ◽  
Mary Maj ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Oxidoreductase Activity ◽  
Model Of Alzheimer’S Disease ◽  
Tgcrnd8 Mouse

scholarly journals P1-093: NOVEL PARTIAL MITOCHONDRIAL COMPLEX I INHIBITORS AS DISEASE-MODIFYING THERAPEUTICS FOR TREATMENT OF ALZHEIMER'S DISEASE

2019 ◽  
Vol 15 ◽  
pp. P270-P270
Author(s):  
Sergey Trushin ◽  
Andrea Stojakovic ◽  
Su-Youne Chang ◽  
Eugenia Trushina
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Disease Modifying

P1-036: MODULATOR OF MITOCHONDRIAL COMPLEX I ACTIVITY AVERTS COGNITIVE IMPAIRMENT IN A SYMPTOMATIC MOUSE MODEL OF FAMILIAL ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_5) ◽  
pp. P280-P281
Author(s):  
Andrea Stojakovic ◽  
Benjamin Gateno ◽  
Su-Youne Chang ◽  
Padraig Flannery ◽  
Utkarsh Tripathi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mouse Model ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Familial Alzheimer’S Disease ◽  
Familial Alzheimer's Disease ◽  
Complex I Activity

scholarly journals Mitochondrial complex I as a therapeutic target for Alzheimer’s disease

2021 ◽  
Author(s):  
Eugenia Trushina ◽  
Sergey Trushin ◽  
Md Fayad Hasan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Target ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex

P1-078: NOVEL PARTIAL MITOCHONDRIAL COMPLEX I INHIBITORS AS DISEASE-MODIFYING THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_5) ◽  
pp. P301-P301
Author(s):  
Sergey Trushin ◽  
Andrea Stojakovic ◽  
Benjamin Gateno ◽  
Liang Zhang ◽  
Kevin Greenman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Disease Modifying

scholarly journals Partial mitochondrial complex I inhibitors as disease‐modifying therapeutics for Alzheimer’s disease

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Sergey Trushin ◽  
Andrea Stojakovic ◽  
Su‐Youne Chang ◽  
Eugenia Trushina
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Complex I ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Disease Modifying
Sign in / Sign up

Export Citation Format

Share Document